IRIS
DEL MASTRO, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 19.224
Totale 19.224
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 19.224
Totale 19.224
Salva come PNG Salva come JPEG
Città #
Genova 12.582
Rapallo 2.505
Genoa 2.289
Vado Ligure 1.753
Bordighera 95
Totale 19.224
Salva come PNG Salva come JPEG
Nome #
Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. 173
Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients 154
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 151
Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate? 150
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 140
Targeting bone metastatic cancer: Role of the mTOR pathway 135
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies 134
Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies 133
Cancer and fertility preservation: international recommendations from an expert meeting 133
Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. 130
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study 127
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 127
Predicting mood disorders in breast cancer patients. 126
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study 126
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 126
Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations 125
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence 123
Pharmacotherapy to protect ovarian function and fertility during cancer treatment 123
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial 122
Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence 121
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 121
Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer 121
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data 119
Management of young women with early breast cancer 119
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 118
Anthracycline-free therapy for HER2-amplified breast cancer 117
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials 117
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 117
Fertility, sexuality and cancer in young adult women 117
Reply to the letter "Safety of fertility preservation in women with breast cancer" 117
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients 115
News on the medical treatment of young women with early-stage HER2-negative breast cancer 115
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients 115
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: Results of an observational study 115
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. 115
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial 114
Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence 114
State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature 113
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 113
Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity 113
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 113
The PREgnancy and FERtility (PREFER) study: An Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients 112
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 112
Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology 111
Reply to the letter to the editor 'Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?' by Rodriguez-Wallberg et al. 111
Exploring the safety of chemotherapy for treating breast cancer during pregnancy 110
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients 109
Circulating tumor DNA using tagged targeted deep sequencing to assess minimal residual disease in breast cancer patients undergoing neoadjuvant chemotherapy 109
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 108
Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study 107
Treatment with aromatase inhibitors and markers of cardiovascular disease 107
Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes 106
Randomized cooperative study of perioperative chemotherapy in breast cancer. 105
Letrozole withdrawal response in locally advanced breast cancer 105
An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project 105
Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study 105
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 104
Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors? 103
Taxane-containing chemotherapy in the treatment of early breast cancer patients 102
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs) 102
Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of Fc gamma RIIIA/Fc gamma RIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 102
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 101
Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells 101
Optimal Adjuvant Chemotherapy Regimens for Patients With Early-Stage Breast Cancer 100
Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives 100
A case where switching end points for clinical trial interpretation might be the right choice 100
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 100
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial 99
Safety of adjuvant aromatase inhibitor therapy 99
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer 98
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. 97
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis 97
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going 97
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors 97
Long-term follow-up of The Intergroup Exemestane Study 96
Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients 96
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis 96
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer) 96
Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 96
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group 95
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole 95
Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications 94
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors 94
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 94
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer 94
A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes 93
Pharmacokinetics of trastuzumab in haemodialysis 93
Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer 93
Optimization of a wga-free molecular tagging-based ngs protocol for ctcs mutational profiling 93
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 93
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer 92
Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer 91
Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients 91
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group 90
Role of dose-dense chemotherapy in high-risk early breast cancer 90
Temporary ovarian suppression with goserelin and ovarian function protection in patients with breast cancer undergoing chemotherapy. 89
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases 89
Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors 88
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients 88
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 88
Totale 10.945
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.723
article - articoli 77.608
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 115
Totale 155.446
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.410 0 0 0 0 589 836 1.128 578 645 885 584 165
2020/20212.223 156 222 222 224 117 195 136 234 111 287 143 176
2021/20222.704 142 108 128 261 73 302 97 616 279 247 96 355
2022/20233.082 274 249 31 283 448 457 79 379 507 27 308 40
2023/20241.855 72 229 60 255 145 193 128 154 80 109 112 318
2024/20251.909 196 444 162 385 722 0 0 0 0 0 0 0
Totale 20.156